# Ono Pharmaceutical Co., Ltd. clinical trials: 112 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 112 trials with Ono Pharmaceutical Co., Ltd. as lead sponsor, 20 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Ono Pharmaceutical Co., Ltd.: 112 rows for $5.60, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ono-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 112
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 25 newest of 112, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 22, 2026 | NCT07832747 | A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT | Ono Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Tenosynovial Giant Cell Tumor | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832747) |
| September 17, 2026 | NCT07825402 | A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P) | Ono Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Multiple System Atrophy, Parkinson Variant | 486 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825402) |
| September 16, 2026 | NCT07823790 | ONO-4915 in Patients With Primary Sjogren's Disease | Ono Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Sjogren's Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823790) |
| September 14, 2026 | NCT07818070 | A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric... | Ono Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Gastric Cancer, Esophagogastric Junction Cancer, Esophageal Adenocarcinoma | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818070) |
| August 26, 2026 | NCT07787208 | A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors | Ono Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Solid Tumors | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07787208) |
| August 6, 2026 | NCT07749768 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and... | Ono Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Ulcerative Colitis (UC) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749768) |
| July 29, 2026 | NCT07734116 | A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma. | Ono Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Pediatric Malignant Solid Tumor and Epithelioid Sarcoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734116) |
| June 1, 2026 | NCT07619157 | A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus | Ono Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Type2 Diabetes Mellitus, Chronic Kidney Disease | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619157) |
| June 1, 2026 | NCT07618377 | Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments | Ono Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Gastrointestinal Stromal Tumors | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07618377) |
| May 18, 2026 | NCT07594158 | A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds | Ono Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Partial Epilepsy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594158) |
| February 24, 2026 | NCT07429266 | INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) | Ono Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Polycythemia Vera | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07429266) |
| September 30, 2025 | NCT07198087 | A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to... | Ono Pharmaceutical Co., Ltd. | Phase 1 | Completed | Primary Central Nervous System Lymphoma (PCNSL) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07198087) |
| September 12, 2025 | NCT07169708 | A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients... | Ono Pharmaceutical Co., Ltd. | Observational | Recruiting | Non Small Cell Lung Cancer NSCLC | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07169708) |
| August 5, 2025 | NCT07104032 | IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) | Ono Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Relapsed/Refractory Primary Central Nervous System Lymphoma | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07104032) |
| April 29, 2025 | NCT06948448 | A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab... | Ono Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Colorectal Cancer | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06948448) |
| April 20, 2025 | NCT06936943 | ONO-4538 Study in Patients With Richter's Transformation | Ono Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Richter's Transformation | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06936943) |
| March 18, 2025 | NCT06881836 | A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease | Ono Pharmaceutical Co., Ltd. | Phase 2 | Completed | Alzheimer Disease | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06881836) |
| February 10, 2025 | NCT06816108 | A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors | Ono Pharmaceutical Co., Ltd. | Phase 1 | Active not recruiting | Solid Tumor, NSCLC | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06816108) |
| February 3, 2025 | NCT06805565 | A Study of ONO-1110 in Patients With Social Anxiety Disorder | Ono Pharmaceutical Co., Ltd. | Phase 2 | Completed | Social Anxiety Disorder (SAD) | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06805565) |
| January 31, 2025 | NCT06803823 | A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia | Ono Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Agitation Associated With Alzheimer's Disease Dementia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06803823) |
| January 24, 2025 | NCT06792136 | A Study of ONO-1110 in Patients With Major Depressive Disorder | Ono Pharmaceutical Co., Ltd. | Phase 2 | Completed | Major Depressive Disorder (MDD | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06792136) |
| December 30, 2024 | NCT06752603 | A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis | Ono Pharmaceutical Co., Ltd. | Phase 2 | Completed | Hunner Type Interstitial Cystitis | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06752603) |
| December 30, 2024 | NCT06752590 | A Clinical Study of ONO-1110 in Patients With Fibromyalgia | Ono Pharmaceutical Co., Ltd. | Phase 2 | Completed | Fibromyalgia | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06752590) |
| December 3, 2024 | NCT06714370 | Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System... | Ono Pharmaceutical Co., Ltd. | Observational | Completed | Primary Central Nervous System Lymphoma (PCNSL) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06714370) |
| November 27, 2024 | NCT06708416 | A Study of ONO-1110 in Patients With Postherpetic Neuralgia | Ono Pharmaceutical Co., Ltd. | Phase 2 | Completed | Postherpetic Neuralgia | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06708416) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 45 |
| Phase 1/2 | 3 |
| Phase 2 | 33 |
| Phase 2/3 | 3 |
| Phase 3 | 25 |
| Phase 4 | 1 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 69 |
| Recruiting | 16 |
| Active not recruiting | 15 |
| Terminated | 8 |
| Not yet recruiting | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Stomach Neoplasms | 6 |
| Diabetes Mellitus, Type 2 | 5 |
| Urinary Bladder, Overactive | 5 |
| Recurrence | 4 |
| Osteoporosis | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Pancreatic Neoplasms | 3 |
| Coronary Artery Disease | 3 |
| Colorectal Neoplasms | 2 |
| Leukemia | 2 |
| Epilepsies, Partial | 2 |
| Neoplasms | 2 |
| Amyotrophic Lateral Sclerosis | 2 |
| Acromegaly | 2 |
| Gastroesophageal Reflux | 2 |
| Lymphoma | 2 |
| Lymphoma, T-Cell | 2 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
| Multiple System Atrophy | 2 |
| Parkinson Disease | 2 |
| Lymphoma, Non-Hodgkin | 2 |
| Venous Thromboembolism | 1 |
| Psoriasis | 1 |
| Myelodysplastic Syndromes | 1 |
| Leukemia, Myeloid | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Structural engineering firms in the United States](https://specstream.ai/data/businesses/structural-engineering-firms/united-states)
- [Colombian restaurants in the United States](https://specstream.ai/data/businesses/colombian-restaurants/united-states)
- [Manufacturing consultants in the United States](https://specstream.ai/data/businesses/manufacturing-consultants/united-states)
- [Ultrasound imaging clinics in the United States](https://specstream.ai/data/businesses/ultrasound-imaging-clinics/united-states)
- [Doner kebab restaurants in the United States](https://specstream.ai/data/businesses/doner-kebab-restaurants/united-states)
